SGX’s relationship with MSCI has long been one of the more consequential index-licensing arrangements in Asian derivatives, underpinning SGX’s MSCI-linked futures and options franchise that captured volume when India-focused contracts became a flashpoint with domestic exchanges. An expansion of that licensing pact into a “broader derivatives suite,” as Singapore Business Review describes it, signals SGX wants to lean further into index-linked contracts as a growth lever rather than compete purely on cash-equities volume. What’s missing from the reporting so far — fee terms, which new indices or asset classes are covered, expected launch dates — matters a great deal to market-data desks and derivatives traders who will need to reprice licensing costs and rework product coverage once specifics land.
An index-licensing deal is only as interesting as the fine print, and none of that fine print has surfaced yet.
Watch for SGX’s next product filing or investor update to clarify whether this covers new MSCI regional or thematic indices, and whether MSCI extracts a richer royalty for widening SGX’s derivatives shelf.
SGX, MSCI expand licensing deal for broader derivatives suite
